Cargando…

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients

BACKGROUND: Monoclonal antibodies (mAbs) that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are predominantly less effective against Omicron variants. Immunocompromised patients often experience prolonged viral shedding, resulting in an increased risk of viral escape. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gliga, Smaranda, Lübke, Nadine, Killer, Alexander, Gruell, Henning, Walker, Andreas, Dilthey, Alexander T, Thielen, Alexander, Lohr, Carolin, Flaßhove, Charlotte, Krieg, Sarah, Pereira, Joanna Ventura, Seraphin, Tobias Paul, Zaufel, Alex, Däumer, Martin, Orth, Hans-Martin, Feldt, Torsten, Bode, Johannes G, Klein, Florian, Timm, Jörg, Luedde, Tom, Jensen, Björn-Erik Ole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619606/ https://www.ncbi.nlm.nih.gov/pubmed/36189631 http://dx.doi.org/10.1093/cid/ciac802

Ejemplares similares

Multicentric Castleman’s disease in HIV patients: a single-center cohort diagnosed from 2008 to 2018
por: Gliga, Smaranda, et al.
Publicado: (2021)

Prevalence of H. pylori among asymptomatic HIV-positive and negative individuals in Central Ethiopia and efficacy of eradication therapy
por: Mesfun, Million Getachew, et al.
Publicado: (2022)

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
por: Jensen, Bjoern, et al.
Publicado: (2021)

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
por: Totschnig, David, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis
por: Däumer, Martin, et al.
Publicado: (2011)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
por: Baldi, Federico, et al.
Publicado: (2023)

Secondary sclerosing cholangitis as a complication of severe COVID‐19: A case report and review of the literature
por: Klindt, Caroline, et al.
Publicado: (2021)

Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Clusters Based on Integrated Genomic Surveillance, Outbreak Analysis and Contact Tracing in an Urban Setting
por: Walker, Andreas, et al.
Publicado: (2021)

Recurrent parvovirus B19 viremia resulting in two episodes of hemophagocytic lymphohistiocytosis
por: Orth, Hans Martin, et al.
Publicado: (2022)

Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort
por: Freise, Noemi F., et al.
Publicado: (2022)

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
por: Huygens, Sammy, et al.
Publicado: (2022)

497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial
por: Dosanjh, Davinder, et al.
Publicado: (2023)

Quantitative analysis of different respiratory specimens on two automated test systems for detection of SARS-CoV-2 RNA
por: Lübke, Nadine, et al.
Publicado: (2023)

Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab
por: Magnus, Clara Luzia, et al.
Publicado: (2022)

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
por: Kreye, Jakob, et al.
Publicado: (2023)

Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
por: Gonzalez-Bocco, Isabel H., et al.
Publicado: (2023)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure
por: Keitel, Verena, et al.
Publicado: (2021)

TIPS and splenorenal shunt for complications of portal hypertension in chronic hepatosplenic schistosomiasis–A case series and review of the literature
por: Nordmann, Tamara, et al.
Publicado: (2021)

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
por: Gupta, Isha, et al.
Publicado: (2022)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Horizontally transferred genes cluster spatially and metabolically
por: Dilthey, Alexander, et al.
Publicado: (2015)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021)

512. Interim Results of a Prospective Cohort Study to Monitor the Emergence of Resistance in Immunocompromised Non-Hospitalized Patients With COVID-19 Who Were Treated with Sotrovimab in Great Britain: LUNAR Study 
por: Breuer, Judith, et al.
Publicado: (2023)

Monitoring of Sotrovimab-Levels as Pre-Exposure Prophylaxis in Kidney Transplant Recipients Not Responding to SARS-CoV-2 Vaccines
por: Aschauer, Constantin, et al.
Publicado: (2023)

SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses
por: Mazzetti, Paola, et al.
Publicado: (2023)

Antigenic escape is accelerated by the presence of immunocompromised hosts
por: Kumata, Ryuichi, et al.
Publicado: (2022)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Aeromonas hydrophilia Infection in an Immunocompromised Host
por: Zhao, Yi, et al.
Publicado: (2021)

Immune response to third SARS‐CoV‐2 vaccination in seronegative kidney transplant recipients: Possible improvement by mycophenolate mofetil reduction
por: Kantauskaite, Marta, et al.
Publicado: (2022)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods
por: Otte, Fabian, et al.
Publicado: (2023)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2022)

Sotrovimab in pediatric cardiac transplant recipients with SARS-CoV2 infection
por: Weber, Sven C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_489ebjorci1d0ven6e81ps7mnn